GSK enters PARP space with TESARO acquisition
Rucaparib gets FDA OK in maintenance use
CHMP backs conditional approval for PARP drug
Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
Lynparza first in class approved in breast cancer
Impressed by survival data, FDA hastens review in expanded patient group
Tesaro’s PARP drug approved in wider ovarian cancer population